Candel Therapeutics (CADL) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.
The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.
The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.
Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.
Price: 8.28, Change: -2.68, Percent Change: -24.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。